학술논문
Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma
Document Type
article
Author
Mei-Chee Tai; Leonidas E. Bantis; Gargy Parhy; Taketo Kato; Ichidai Tanaka; Chi-Wan Chow; Junya Fujimoto; Carmen Behrens; Tetsunari Hase; Koji Kawaguchi; Johannes F. Fahrmann; Edwin J. Ostrin; Kohei Yokoi; Toyofumi F. Chen-Yoshikawa; Yoshinori Hasegawa; Samir M. Hanash; Ignacio I. Wistuba; Ayumu Taguchi
Source
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2331 (2024)
Subject
Language
English
ISSN
1422-0067
1661-6596
1661-6596
Abstract
Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit from adjuvant chemotherapy. To identify circulating miRNAs useful for predicting recurrence in early-stage LUAD, we performed miRNA microarray analysis with pools of pretreatment plasma samples from patients with stage I LUAD who developed recurrence or remained recurrence-free during the follow-up period. Subsequent validation in 85 patients with stage I LUAD resulted in the development of a circulating miRNA panel comprising miR-23a-3p, miR-320c, and miR-125b-5p and yielding an area under the curve (AUC) of 0.776 in predicting recurrence. Furthermore, the three-miRNA panel yielded an AUC of 0.804, with a sensitivity of 45.8% at 95% specificity in the independent test set of 57 stage I and II LUAD patients. The miRNA panel score was a significant and independent factor for predicting disease-free survival (p < 0.001, hazard ratio [HR] = 1.64, 95% confidence interval [CI] = 1.51–4.22) and overall survival (p = 0.001, HR = 1.51, 95% CI = 1.17–1.94). This circulating miRNA panel is a useful noninvasive tool to stratify early-stage LUAD patients and determine an appropriate treatment plan with maximal efficacy.